Drug Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Potential for improved product quality and cost/time savings is reviving interest in perfusion technology.

The Potential of Perfusion

Vetter’s Vetter-Ject closure system for prefilled syringes has an integrated needle hub and shield and is designed for sensitive compounds, such as biologics.

Syringe Closure System Allows Use of Highly Sensitive Compounds

Agnes Shanley is senior editor of Pharmaceutical Technology.

Currently, pharma has only scratched the surface of the potential value of repurposing drugs, says consultant Hermann Mucke. Contract service partners are playing a more prominent role, but could play an even larger one in these efforts.

Recovering the Value of Repurposed Drugs

Investment in Powdersize adds particle-size control solutions to Xcelience’s capabilities.

Xcelience Makes Investment in Powdersize

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

The Generic Pharmaceutical Association and the Biosimilars Council wrote an open letter to President Barack Obama protesting the patent protections outlined in the Trans-Pacific Partnership.

Biosimilars Council Opposes IP Provisions in Trans-Pacific Partnership

FDA approved the drug for a more narrow indication in the US than did EMA for Repatha, Praluent’s fiercest competitor.

FDA Approves Praluent, the First PCSK9 Inhibitor in the US

EMA gives GSK’s malaria candidate vaccine a positive opinion for the prevention of malaria in young children in sub-Saharan Africa.

GSK’s Malaria Vaccine Gets Positive Opinion from EMA

The Catalent Applied Drug Delivery Institute and AAPS recognize four groups for emerging scientific talent and academic excellence.

Academic Groups Recognized for Drug Delivery Papers

A Federal circuit appeals court ruled that a biosimilar manufacturer will have to wait 6 months after FDA approval to commercially launch its medication.

Biosimilar Manufacturers Must Wait Six Months After Approval to Market Product

GSK accelerates delivery timeline for US quadrivalent flu vaccine.

Formulation and Drug Delivery